Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Type 2 Diabetes with Uncontrolled Hypertension
NCT01195662Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2010
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and hypertension (HTN) comparing Dapagliflozin 10 mg with Placebo (2 arms). Primary endpoints: Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure at 12 weeks and Adjusted Mean Change From Baseline in Hemoglobin A1c at 12 weeks. Started Oct 2010; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on NCT01195662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01195662.